Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,392.26 +134.05 (+0.21%) CMC Crypto 200
1,350.96 -9.36 (-0.69%)
Genscript Biotech Corporation (1548.HK)
- PR Newswire
GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market
GenScript Biotech Corporation, renowned for its relentless innovation in synthetic biology and industry-leading gene synthesis services, is excited to announce the launch of its newest offering, GenScript FLASH Gene service, the ultra-fast sequence-to-plasmid (S2P) service. This flagship offering addresses the urgent demand for delivering gene constructs with unmatched speed, quality, and cost-efficiency.
- PR Newswire
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications
GenScript Biotech Corporation, a global leader in life science research tools and services, has today announced the expansion of its in vitro transcription (IVT) RNA synthesis portfolio to include self-amplifying RNA (saRNA). This cutting-edge addition reinforces GenScript's position at the forefront of IVT RNA technology, offering a new and novel format for researchers working in applications such as vaccine, cancer immunotherapy, and gene or cell therapy development.
- Business Wire
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
SAN FRANCISCO, April 25, 2024--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation (GenScript), one of the world's leading providers of life-science research tools and services, today announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.
